Zevra Therapeutics

We are a commercial-stage company committed to redefining what is possible in bringing life-changing therapies to people living with rare diseases.
$ZVRA

[Zevra Therapeutics @zevratx]

Today, we recognize #Juneteenth, a day that commemorates the end of slavery in the United States and serves as an opportunity to reflect on our shared history.
As we mark this day, we reaffirm our commitment to fostering a culture of respect, inclusion, and opportunity for all.

[Zevra Therapeutics @zevratx]

In a recent @FiercePharma interview, our CEO Neil McFarlane discusses the importance of increasing diagnosis rates for Niemann-Pick disease type C (NPC) and future growth opportunities.

Read the article: https://t.co/dqLaNiMUqs

#RareDisease #NPC

[Zevra Therapeutics @zevratx]

Navigating Niemann-Pick disease type C (NPC) can be complex, and questions can come up along the way.

Explore our NPC Knowledge Hub for information on symptoms, diagnosis, and living with NPC:
https://t.co/kSqul2HTSd
#RareDisease #NPC

[Zevra Therapeutics @zevratx]

We're pleased to announce the FDA Orange Book listing of a U.S. patent that strengthens exclusivity protection through November 2041, reinforcing our commitment to advancing innovation for the rare disease community.

Learn more: https://t.co/lDI9qX9974

[Zevra Therapeutics @zevratx]

This June, we recognize Pride Month and the importance of fostering a workplace where all employees feel respected, supported, and able to contribute their best. #PrideMonth

[Zevra Therapeutics @zevratx]

A sweet afternoon for a great cause! 🍦 Members of the Zevra team enjoyed the Jimmy Fund’s Scooper Bowl while supporting cancer care and research. Proud to be part of such an impactful event. #ScooperBowl #JimmyFund

[Zevra Therapeutics @zevratx]

A great few days at the Ara Parseghian Medical Research Foundation Annual Conference 2026. We appreciated the chance to spend time with colleagues, families, advocates, and others from across the Niemann-Pick disease type C (NPC) community.

[Zevra Therapeutics @zevratx]

Thanks to Business of Biotech for hosting Neil McFarlane, our President and CEO on last week’s podcast.

Listen to the full episode: https://t.co/jHajd8geQh

[Zevra Therapeutics @zevratx]

Looking forward to attending the Ara Parseghian Medical Research Foundation Annual Conference 2026.

Excited to connect with the NPC community and support continued progress.
#NPCawareness #RareDisease

[Zevra Therapeutics @zevratx]

A great week at American Psychiatric Association Annual Meeting 2026 and Society for Inherited Metabolic Disorders Annual Meeting 2026.
Grateful for the conversations, insights, and connections with the community. Looking forward to continuing the momentum.

[Zevra Therapeutics @zevratx]

We’re excited to share that the sponsored genetic testing program with GeneDx is officially live!
NPC Detect expands access to exome sequencing for eligible individuals with suspected NPC, helping support earlier diagnosis in this rare, progressive condition.

[Zevra Therapeutics @zevratx]

Excited to present two encore posters at #SIMD2026 on May 18!
📌 Poster #096 (7–8 PM): NPC002 trial results of arimoclomol + miglustat
📌 Poster #129 (8–9 PM): NPC1 genotype analysis from US expanded access program
#NPC #RareDisease

[Zevra Therapeutics @zevratx]

Zevra is wearing red for #REDS4VEDS
We’re raising awareness for vascular Ehlers-Danlos Syndrome (VEDS), a rare, life-threatening condition. Learn more about VEDS: https://t.co/9pHpNNld02

[Zevra Therapeutics @zevratx]

Next week, the Zevra team is heading to two meetings!
📍American Psychiatric Association (APA) Annual Meeting 2026 Booth #1837
📍 Society for Inherited Metabolic Disorders (SIMD) Annual Meeting 2026 Booths #15 & #36
Excited to connect with colleagues and partners at both events.

[Zevra Therapeutics @zevratx]

At Zevra, we redefine what is possible in bringing life-changing therapies to people living with rare diseases

Our values guide us every day as we advance therapies for rare disease communities.

#RareDisease #CompanyCulture

[Zevra Therapeutics @zevratx]

$ZVRA reports first quarter 2026 financial results and provides a corporate update.
Join our LIVE webcast TODAY at 4:30 p.m. ET: https://t.co/3tKaFIJ55I
For more, find the full release here: https://t.co/POWPHCf7Ec
#RareDiseases
#InvestorRelations
#IR

[Zevra Therapeutics @zevratx]

We’re proud to be featured in PharmaBoardroom’s rare disease spotlight alongside leaders from the FDA, NIH, policy, advocacy, research institutions & industry, all advancing progress for the rare disease community. Read the article here: https://t.co/6oJ6sOVsaQ
#RareDisease

[Zevra Therapeutics @zevratx]

Great week at #AANAM!
We enjoyed hosting our booth and connecting with the neurology community.

Thanks to everyone who stopped by. We’re excited by the momentum and look forward to what’s next.

[Zevra Therapeutics @zevratx]

$ZVRA will report first quarter 2026 financial results and provide a corporate update on Wednesday, May 6, 2026, with a live webcast at 4:30 p.m. ET.

For registration details, see the release: https://t.co/hFaf69NQGD

#RareDiseases
#InvestorRelations
#IR

[Zevra Therapeutics @zevratx]

Good luck to everyone running the 130th Boston Marathon today!

Our team is cheering on all the runners, volunteers, and supporters who make this incredible day possible. Wishing you a strong race and great weather out there!

#BostonMarathon #BostonStrong